Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
We are supporting an international Pharmaceutical company in the search for an experienced MSAT Manager to lead client-facing technical projects and support new product introductions within a GMP aseptic manufacturing environment. Key Responsibilities Act as technical
RhyGaze is a biotech company developing transformative gene therapies to restore vision in patients with blindness. Our programs target patients with blinding retinal diseases, and we are committed to bringing life‑changing treatments to those in need.
Revolution Medicines is seeking a Director, Regulatory Affairs, Europe to lead regulatory strategy and execution for EU/EEA/UK/Switzerland oncology programs. You will drive MAA filings, lifecycle management, and proactive engagement with EMA, MHRA and Swissmedic, guiding cross‑functional teams
Innovative Biopharmaceutical Company | Northwestern SwitzerlandShape the Regulatory Future of Innovative Small Molecule TherapiesOur client is an innovative and fast-growing biopharmaceutical company developing breakthrough therapies for patients with high unmet medical needs. As the development portfolio
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‐addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
gloor&lang AG in Basel seeks a senior Regulatory Affairs CMC expert to lead global CMC strategy for development and registration of small molecule therapies, shaping regulatory submissions (Module 3) and lifecycle management in collaboration with CMC
Associate Safety Director (m/f/d) (LSW)- Drug safety/pharmacovigilance/ English Background: Portfolio Safety Scientists (PCS-Sci) provide safety science and pharmacovigilance support to molecules across the Roche portfolio. As a group, they are responsible for all aspects of safety
RhyGaze is a biotech company developing transformative gene therapies to restore vision in patients with blindness. Our programs target patients with blinding retinal diseases, and we are committed to bringing life-changing treatments to those in need.